A systematic review and meta‐analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections
Abstract
Background: Isavuconazole is a novel triazole antifungal agent. However, the previous outcomes were highlighted by statistical heterogeneity. This meta‐analysis aimed to validate the efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections (IFIs) compared with other antifungal agents (amphotericin B, voriconazole and posaconazole).Methods: Scopus, EMBASE, PubMed, CINAHL and Ichushi databases were searched for relevant articles that met the inclusion criteria through February 2023. Mortality, IFI rate, discontinuation rate of antifungal therapy and incidence of abnormal hepatic function were evaluated. The discontinuation rate was defined as the percentage of therapy discontinuations due to adverse events. The control group included patients who received other antifungal agents.Results: Of the 1784 citations identified for screening, 10 studies with an overall total of 3037 patients enrolled. Isavuconazole was comparable with the control group in mortality and IFI rate in the treatment and prophylaxis of IFIs, respectively (mortality, odds rate (OR) 1.11, 95% confidential interval (CI) 0.82–1.51; IFI rate, OR 1.02, 95% CI 0.49–2.12). Isavuconazole significantly reduced the discontinuation rate in the treatment (OR 1.96, 95% CI 1.26–3.07) and incidence of hepatic function abnormalities in the treatment and prophylaxis, compared with the control group (treatment, OR 2.31, 95% CI 1.41–3.78; prophylaxis, OR 3.63, 95% CI 1.31–10.05).Conclusions: Our meta‐analysis revealed that isavuconazole was not inferior to other antifungal agents for the treatment and prophylaxis of IFIs, with substantially fewer drug‐associated adverse events and discontinuations. Our findings support the use of isavuconazole as the primary treatment and prophylaxis for IFIs.Keywords
This publication has 39 references indexed in Scilit:
- Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution MethodAntimicrobial Agents and Chemotherapy, 2015
- Invasive fungal infections in solid organ transplant recipientsClinical Microbiology and Infection, 2014
- Micafungin for the treatment of invasive aspergillosisJournal of Infection, 2014
- Isavuconazole Therapy Protects Immunosuppressed Mice from MucormycosisAntimicrobial Agents and Chemotherapy, 2014
- ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013Clinical Microbiology and Infection, 2014
- Isavuconazole (BAL4815) Pharmacodynamic Target Determination in an In Vivo Murine Model of Invasive Pulmonary Aspergillosis against Wild-Type and cyp51 Mutant Isolates of Aspergillus fumigatusAntimicrobial Agents and Chemotherapy, 2013
- Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis ModelAntimicrobial Agents and Chemotherapy, 2013
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- Voriconazole in clinical practiceJournal of Chemotherapy, 2012
- Liposomal amphotericin B: what is its role in 2008?Clinical Microbiology and Infection, 2008